These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 742337)

  • 1. Study of the activity of antithrombin-III in latent cholestasis. (A clinico-pharmacological study of the relationship between antithrombin-III activity and steroid cholestasis).
    Horváth T; Nagy I; Gógl A
    Acta Med Acad Sci Hung; 1978; 35(2):105-13. PubMed ID: 742337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Oral contraceptive agents and antithrombin III].
    Kamenov V; Nalbanski B
    Akush Ginekol (Sofiia); 1990; 29(1):60-3. PubMed ID: 1695492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heparin cofactor II levels are increased by the use of combined oral contraceptives.
    Mackie IJ; Segal H; Burren T; Gallimore M; Walshe KJ; Robinson G; Machin SJ
    Blood Coagul Fibrinolysis; 1990 Dec; 1(6):647-51. PubMed ID: 2133244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in haemostatic variables induced by oral contraceptives containing 50 micrograms or 30 micrograms oestrogen: absence of dose-dependent effect on PAI-1 activity.
    Scarabin PY; Plu-Bureau G; Zitoun D; Bara L; Guize L; Samama MM
    Thromb Haemost; 1995 Sep; 74(3):928-32. PubMed ID: 8571323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased heparin cofactor II levels in women taking oral contraceptives.
    Toulon P; Bardin JM; Blumenfeld N
    Thromb Haemost; 1990 Nov; 64(3):365-8. PubMed ID: 2096488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical aspects of acquired antithrombin III deficiency].
    von Blohn G; Hellstern P; Köhler M; Scheffler P; Wenzel E
    Behring Inst Mitt; 1986 Feb; (79):200-15. PubMed ID: 3718407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemostatic effects of oral contraceptives in women who developed deep-vein thrombosis while using oral contraceptives.
    Bloemenkamp KW; Rosendaal FR; Helmerhorst FM; Koster T; Bertina RM; Vandenbroucke JP
    Thromb Haemost; 1998 Sep; 80(3):382-7. PubMed ID: 9759614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antithrombin III deficiency, deep venous thrombosis, and oral contraceptive use.
    Werner MJ
    J Adolesc Health; 1995 Sep; 17(3):189-92. PubMed ID: 8519788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Surveillance of women taking oral contraceptives by determination of antithrombin III].
    Benoit MO; Raichvarg D; Caillens H; Neau C
    Nouv Presse Med; 1979 Feb; 8(7):528-9. PubMed ID: 461171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oestrogen containing oral contraceptives and antithrombin III activity.
    Rákóczi I; Nagy I; Szigetvári I; Losonczy H; Hadnagy J; Gáti I
    Acta Physiol Acad Sci Hung; 1974; 45(3-4):281-6. PubMed ID: 4471272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The determination of antithrombin III. Comparison of six methods. Effect of oral contraceptive therapy.
    Bounameaux H; Duckert F; Walter M; Bounameaux Y
    Thromb Haemost; 1978 Jun; 39(3):607-15. PubMed ID: 705689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Action of hormonal contraceptives on the coagulation system and some of its inhibitors.
    Misz M; Beck P
    Acta Med Hung; 1986; 43(3):301-10. PubMed ID: 2438639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Oral contraceptives and cholestasis].
    Richter J; Ohlen J; Balletshofer C; Pause H
    Verh Dtsch Ges Inn Med; 1972; 78():1538-9. PubMed ID: 4665603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the prethrombotic state in pregnancy and in women using oral contraceptives.
    Levine AB; Teppa J; McGough B; Cowchock FS
    Contraception; 1996 May; 53(5):255-7. PubMed ID: 8724613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of levenogesterol (Norplant) contraception on coagulation as measured by antithrombin-III levels.
    Pryor JA; Cooper KR; Bass JD; Hampton HL; Rock WA; Morrison JC
    J Miss State Med Assoc; 1996 Oct; 37(10):777-9. PubMed ID: 8908950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathophysiology and clinical aspects of fibrinolysis and inhibition of coagulation. Experimental and clinical studies with special reference to women on oral contraceptives and selected groups of thrombosis prone patients.
    Jespersen J
    Dan Med Bull; 1988 Feb; 35(1):1-33. PubMed ID: 3277796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral contraceptives and deep venous thrombosis with pulmonary embolism.
    Bouché RT; Medawar SJ; Dockery GL
    J Foot Surg; 1982; 21(4):297-301. PubMed ID: 7186920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma antithrombin III activity in normal pregnancy.
    Weiner CP; Brandt J
    Obstet Gynecol; 1980 Nov; 56(5):601-3. PubMed ID: 7432731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Observations with a combined oral contraceptive (Rigevidon) containing minimum oestrogen dose.
    Karsay K
    Ther Hung; 1980; 28(1):17-20. PubMed ID: 7281074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Oral contraceptives and antithrombin III].
    Stormorken H
    Tidsskr Nor Laegeforen; 1985 Nov; 105(32):2333. PubMed ID: 4082148
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.